^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors

Excerpt:
...Three GEP-NET patients with TP53 mutations demonstrated a durable response to pazopanib, either as PR or achievement of stable disease (Figure 2)…
DOI:
10.18632/oncotarget.6602